Asia-Pacific gastric cancer market set to experience strong growth to $2.7 billion by 2022
The Asia-Pacific (APAC) gastric cancer market is set to rise from $1.3 billion in 2015 to $2.7 billion by 2022, at a strong compound annual growth rate of 11.4%, according to business intelligence provider new research
The companys latest report states that the market will be driven by the increasing prevalence of gastric cancer, higher levels of health insurance coverage, and improving disease awareness. Indeed, strong awareness of the disease and a widespread screening program in Japan have already led to a higher number of cases being diagnosed at stage I, increasing the treatment-receiving population.
Gayathri Kanika, Analyst states: In line with improved diagnosis rates, the anticipated approval of various monoclonal antibodies (mAbs) over the forecast period will drive treatment rates across all lines of therapy and generate higher sales in the gastric cancer market.
Currently, the gastric cancer treatment landscape largely comprises generic chemotherapies, which provide limited clinical benefit and cause serious side effects. However, the current pipeline is strong, with targeted therapies expected to be launched during the forecast period.
Get sample report at @ : https://marketreportscenter.com/request-sample/420367
A new class of drug approved for the treatment of gastric cancer, targeting vascular endothelial growth factor receptor, is Cyramza (ramucirumab), a mAb used for second- and third-line therapy for gastric cancer. Research expects Cyramza to garner rapid uptake, as it is being established as the standard of care for the second-line advanced setting, with its label expected to expand to cover the HER2-negative first-line setting within the forecast period.
Perjeta (pertuzumab) is being developed in combination with Herceptin for the treatment of gastric cancer, on the assumption that the combination will yield superior results. The response rate shown in a Phase II trial which compared the efficacy of Herceptin/Perjeta combination with that of Herceptin plus chemotherapy was higher for the Herceptin/Perjeta combination. Perjeta, once approved, will likely replace the current standard of first-line treatment for HER2-positive gastric cancer.
Kanika concludes: Despite their promise, the anticipated premium pricing of mAbs will make affordability a barrier for the marketing of these drugs in India and China, where there are no strong reimbursement frameworks and most expenses are paid out-of-pocket by the patient.
Moreover, increasing cost-consciousness in the other major Asian markets, such as Japan and South Korea, will limit premium pricing opportunities for pipeline agents. Drug companies will need to consider the changing reimbursement landscape when determining the pricing strategies for their drugs in these markets.
- Comments provided by Gayathri Kanika, Analyst
Browse full report with TOC @ : https://marketreportscenter.com/reports/420367/gastric-cancer-therapeutics-in-asia-pacific-markets-to-2022-growth-driven-by-increasing-prevalence-and-launch-of-targeted-therapies
Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach and is the fifth-most common cancer globally. There are many types of gastric cancer, but adenocarcinoma is the most common type and is diagnosed in 95% of cases. The life expectancy and survival rate for gastric cancer is heavily dependent on the stage of the disease when diagnosed. In Asia-Pacific, most of the incident cases of gastric cancer are diagnosed at the late stage and in patients over the age of 60. As the aged population continues to grow, the prevalence of gastric cancer will increase. This, coupled with increasing early diagnosis and an improved survival rate, will drive revenue growth. Due to its indolent nature, the disease remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved targeted therapeutic options. The current marketed products landscape comprises a wide range of treatment options, including HER2-targeted therapy, angiogenesis inhibitors and new chemotherapies. Nevertheless, significant unmet need remains for products that can treat HER2-negative gastric cancer patients. However, the gastric cancer market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on targeted therapies.
In the current market, patients with HER2-positive gastric cancer can be treated with targeted therapies, such as Herceptin, while HER2-negative patients still receive chemotherapy regimens as the first-line treatment. The market will be driven by recently launched products and upcoming targeted therapies during the forecast period. The main restraints will be the low penetration of new targeted therapies, owing to their high price, and constrained healthcare budgets.
The Asia-Pacific gastric cancer market is forecast to grow at a compound annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in 2022.
- How will angiogenesis inhibitors contribute to growth?
- What effect will the patent expirations of branded therapies have on market value?
The pipeline contains a range of molecule types and molecular targets, including those that are well-established in gastric cancer and novel targeted therapies.
- Which molecular targets appear most frequently in the pipeline?
- Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
- What are the most promising first-in-class targets for gastric cancer?
- Will the current first-in-class targets have broader therapeutic potential across the Asia-Pacific markets?
- Will the pipeline address unmet needs such as a lack of targeted treatments for HER2-negative gastric cancer patients?
Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced targeted therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?
Licensing deals are the most common form of strategic alliance in gastric cancer, with total deal values ranging from under $10m to over $200m.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict gastric cancer market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals.
Receive Discount at @ : https://marketreportscenter.com/request-discount/420367